Data from the trial supported the FDA’s accelerated approval of sotorasib in May, for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy. This evidence concerns the gene KRAS and non-small cell lung carcinoma.